[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609438":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":41,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of Florida","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Kari S Bastow, BS","CONTACT","352-265-8827","kari.bastow@ufhealth.org",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Amy Carrao-Tackett, MPH","352-265-0680","amy.carrao-tackett@ufhealth.org",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Gainesville","Florida","32610","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-82.32483,29.65163,{"lat":30,"lon":29},[33,37,39],{"name":34,"role":11,"phone":35,"phoneExt":7,"email":36},"David Iglesias, MD","352-265-8200","iglesiad@ufl.edu",{"name":38,"role":11,"phone":7,"phoneExt":7,"email":17},"Amy Carrao-Tackett",{"name":34,"role":40,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[44],{"name":45,"class":46},"Florida Department of Health","OTHER_GOV","100609438","using-plasma-human-papillomavirus-hpv-related-deoxyribonucleic-acid-dna-and-ribonucleic-acid-rna-to-follow-response-of-cervical-cancer-to-surgery-radiation-and-chemotherapy-100609438",false,"NCT07214584","Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy","Inclusion Criteria:\n\n* 18 years and older\n* HPV-associated squamous cell, adenocarcinoma, or adenosquamous cancers of the uterine cervix with evaluable disease\n* Diagnosed with American Joint Committee on Cancer (AJCC) stage I or higher, or metastatic disease.\n* Presence of evaluable disease on pre-treatment standard of care imaging with plans to obtain serial post-treatment standard of care imaging\n* Agree to perform the required research-related blood tests and cervical mucous testing.\n\nExclusion Criteria:\n\n* Unable to consent or refusal to sign a consent form\n* Not meet any inclusion criteria\n* Unable to comply with follow up scheduling.\n* Diagnosed with a synchronous malignancy requiring cancer-directed therapy","FEMALE","18 Years","89 Years",{"count":57,"type":58},55,"ESTIMATED","OBSERVATIONAL","The goal of this study is to test two commercially available technologies for their ability to detect treatment response in patients with cervical cancer following surgery, radiation, and chemotherapy: one based on polymerase chain reaction (PCR; NavDx) and the other on branched DNA (Quantivirus HPV \\[DNA\\]). A 9-month feasibility study will be performed to examine the side-by-side utility of both NavDx and Quantivirus HPV DNA assays in predicting cervical cancer treatment response.\n\nThese tests could prove to be highly sensitive methods for evaluating minimal residual disease and for quantitation of response to surgery, radiation, and chemotherapy in patients with cervical cancer.\n\nPrimary Goal:\n\nFeasibility for NavDx HPV DNA assay (Naveris, Inc) to be used for personalized prediction of tumor response before and after treatment.\n\nSecondary Goals:\n\n1. Comparability of the Quantivirus HPV DNA\u002FmRNA assay (DiaCarta, Inc) with the NavDx HPV DNA assay and,\n2. Feasibility of the Quantivirus technology for measuring treatment response within the first day to 2 weeks of radiation, surgery, or a new chemotherapy.",[62,63],"Cervical Cancer","Human Papilloma Virus (HPV)",[65,66,62,67],"HPV","HPV Positive Cervical Cancer","Recurrent Cervical Cancer","2026-02-09",{"date":70,"type":71},"2026-02-12","ACTUAL",{"date":73,"type":71},"2025-12-15",{"date":75,"type":58},"2026-12-31",{"name":5,"class":6},1]